Phreesia (NYSE:PHR) Issues Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Phreesia (NYSE:PHR) announced its earnings results on Wednesday. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.06, RTT News reports. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. During the same quarter in the previous year, the business earned ($0.05) EPS. Phreesia updated its FY 2026 guidance to EPS.

Phreesia Trading Up 3.4%

NYSE PHR opened at $24.88 on Wednesday. Phreesia has a twelve month low of $17.07 and a twelve month high of $30.53. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. The stock has a market cap of $1.48 billion, a price-to-earnings ratio of -16.93 and a beta of 0.74. The firm’s 50 day moving average price is $25.03 and its two-hundred day moving average price is $25.23.

Analysts Set New Price Targets

PHR has been the topic of several recent analyst reports. Wall Street Zen cut Phreesia from a “buy” rating to a “hold” rating in a report on Saturday. DA Davidson dropped their target price on Phreesia from $36.00 to $34.00 and set a “buy” rating on the stock in a report on Monday, April 14th. Needham & Company LLC reissued a “buy” rating and set a $29.00 target price on shares of Phreesia in a report on Thursday, March 13th. KeyCorp decreased their price target on shares of Phreesia from $30.00 to $28.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 16th. Finally, Canaccord Genuity Group lifted their price target on shares of Phreesia from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, March 13th. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.33.

Insiders Place Their Bets

In other Phreesia news, SVP David Linetsky sold 3,944 shares of Phreesia stock in a transaction that occurred on Tuesday, April 8th. The shares were sold at an average price of $23.85, for a total transaction of $94,064.40. Following the transaction, the senior vice president now directly owns 221,738 shares in the company, valued at approximately $5,288,451.30. The trade was a 1.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Balaji Gandhi sold 1,827 shares of Phreesia stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $27.46, for a total transaction of $50,169.42. Following the transaction, the chief financial officer now owns 103,591 shares in the company, valued at approximately $2,844,608.86. The trade was a 1.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 42,474 shares of company stock worth $1,023,208. Corporate insiders own 5.80% of the company’s stock.

Institutional Investors Weigh In On Phreesia

A number of institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. boosted its stake in shares of Phreesia by 0.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company’s stock valued at $15,336,000 after buying an additional 2,402 shares during the period. AQR Capital Management LLC boosted its stake in shares of Phreesia by 471.2% during the 1st quarter. AQR Capital Management LLC now owns 160,032 shares of the company’s stock valued at $4,090,000 after buying an additional 132,015 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Phreesia by 3.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company’s stock valued at $1,599,000 after buying an additional 2,158 shares during the period. Royal Bank of Canada boosted its stake in shares of Phreesia by 208.8% during the 1st quarter. Royal Bank of Canada now owns 24,119 shares of the company’s stock valued at $617,000 after buying an additional 16,309 shares during the period. Finally, NewEdge Advisors LLC boosted its stake in shares of Phreesia by 262.7% during the 1st quarter. NewEdge Advisors LLC now owns 15,437 shares of the company’s stock valued at $395,000 after buying an additional 11,181 shares during the period. Institutional investors and hedge funds own 92.10% of the company’s stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.